Waters Corporation

Waters Corporation

WAT

$449.33

Updated: 03/11/2026, 04:29:00

Market Cap
$44.12B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US

No historical data available

Company Profile

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.

USD
NYSE
CEO: Udit Batra
Employees: 7,900
https://www.waters.com
Asset Summaries
Latest generated summaries for WAT

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
WAT-10-k-fy2025.html2.9 MBtext/htmlENFiled 23/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 78 KPI observations

Revenue

3.2B

FY 2025 · Reported

Net income

0.6B

FY 2025 · Reported

Gross margin

59.3%

FY 2025 · Calculated

Free cash flow

N/A

FY — · Reported

R&D intensity

6.2%

FY 2025 · Calculated

Share repurchases

0.0B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Product families
Product lines: LC, MS, TA, Wyatt, consumables, Analytical Standards/Reagents, ERA, VICAM

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Core business

Analytical instruments leader in chromatography, mass spectrometry, thermal analysis; LC-MS systems plus consumables and service

99%
Source evidence
“has pioneered innovations in chromatography, mass spectrometry and thermal analysis serving life, materials and food sciences for more than 65 years”

Segments

Two operating segments (Waters and TA) aggregated into one reporting segment; reorganized into four segments after BDS acquisition

98%
Source evidence
“Following the BDS Business Acquisition, the Company has reorganized the existing and new divisions into the following four segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences”

TA (thermal analysis, rheometry, calorimetry)

TA's thermal analysis, rheometry and calorimetry products manufactured in New Castle DE, Eden Prairie MN, Lindon UT, and Hüllhorst, Germany; competitors PerkinElmer, NETZSCH, Malvern PANalytical, Spectris, Anton-Paar

90%
Source evidence
“TA's thermal analysis, rheometry and calorimetry products are manufactured and distributed at the Company's New Castle, Delaware, Eden Prairie, Minnesota, Lindon, Utah and Hüllhorst, Germany facilities.”

Customer end markets

Pharmaceutical, clinical, industrial, nutritional safety, environmental, academic and governmental customers in R&D, QA and lab applications

98%
Source evidence
“The Company’s products are used by pharmaceutical, clinical, biochemical, industrial, nutritional safety, environmental, academic and governmental customers working in research and development, quality assurance and other laboratory applications”

Product families

LC instruments, MS, columns/consumables, TA thermal analysis, Wyatt light scattering, Empower/HPLC CONNECT software, IVD products, and post-BDS diagnostics/flow cytometry

97%
Source evidence
“The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (“HPLC”), ultra-performance liquid chromatography (“UPLC” and together with HPLC, referred to as “LC”) and mass spectrometry (“MS”) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans”

Product lines: LC, MS, TA, Wyatt, consumables, Analytical Standards/Reagents, ERA, VICAM

Product families include LC instruments/columns (ACQUITY UPLC), MS, TA thermal analysis/rheometry/calorimetry, Wyatt instruments, VICAM kits, Analytical Standards and Reagents, and ERA product lines

85%
Source evidence
“VICAM manufactures antibody-linked resins and magnetic beads that are packed into columns and kits in Milford, Massachusetts.”

Operations and dependencies

Raw materials and conflict minerals

Raw materials include high temperature alloy sheet metal, castings, forgings, pre-plated metals and electrical components; conflict minerals (tantalum, tin, gold, tungsten) subject to Dodd-Frank disclosure

85%
Source evidence
“certain materials (tantalum, tin, gold and tungsten), known as conflict minerals”

Manufacturing footprint

Manufacturing in the U.S., Ireland, U.K. and Singapore; sells and services customers in over 35 countries outside the U.S.

96%
Source evidence
“we have manufacturing operations in the U.S., Ireland, U.K. and in Singapore where we utilize subcontractors with worldwide capabilities”

Global manufacturing footprint

Manufacturing in Milford MA, Taunton MA ($251M expansion completed Feb 2024), Wexford Ireland, Wilmslow and Birmingham England, New Castle DE, Eden Prairie MN, Lindon UT, Hüllhorst Germany, Santa Barbara CA, Golden CO, plus Singapore contract manufacturing

90%
Source evidence
“In February 2024, the Company completed an expansion of its Taunton manufacturing facility, incurring costs of approximately $251 million in connection with the expansion between 2018 and 2024.”

Concentrated single-site manufacturing for certain product lines

Manufacturing of certain product lines is concentrated in one or a few plants; disruption may not be transitionable to other sites or third parties.

90%
Source evidence
“the manufacturing of certain of our product lines is concentrated in one or a few of our plants as a result of many factors, including site licensing and regulatory oversight”

Outsourced manufacturing of LC instruments to contract manufacturers in Singapore

The Company outsources manufacturing of certain LC instrument systems and components to well-established contract manufacturing firms in Singapore

90%
Source evidence
“the Company outsources the manufacturing of certain LC instrument systems and components to well-established contract manufacturing firms in Singapore”

Employees

Approximately 7,900 employees at Dec 31, 2025 (7,600 in 2024; 7,900 in 2023); ~39% in the US; not unionized

95%
Source evidence
“The Company employed approximately 7,900, 7,600 and 7,900 employees at December 31, 2025, 2024 and 2023, respectively, with approximately 39% of the Company's employees located in the United States.”

Positioning and strategy

BDS Business Acquisition

Acquired BD's BDS Business for $16.8B including assumed debt via Reverse Morris Trust; BD shareholders received ~39.2% of combined company

99%
Source evidence
“completed the acquisition (the “BDS Business Acquisition”) of the Biosciences and Diagnostic Solutions businesses (the “BDS Business”) of Becton, Dickinson and Company (“BD”), for a total purchase price, including assumed debt, of $16.8 billion”

BDS Business Acquisition from BD (Reverse Morris Trust)

On July 13, 2025, Waters agreed to acquire the BDS Business from BD via Reverse Morris Trust; expects ~$200M cost synergies within 3 years and ~$290M revenue synergies within 5 years

95%
Source evidence
“The Company expects to generate cost synergies of approximately $200 million within three years of the completion of the BDS Business Acquisition ... and revenue synergies of approximately $290 million within five years”

Prior technology acquisitions

Added TA Instruments (1996), Micromass (1997), Wyatt Technology (May 2023, $1.3B per cash flows), Halo Labs (2025), BDS (2026)

95%
Source evidence
“the Company has added four significant and complementary technologies to its range of products with the acquisitions of TA Instruments in May 1996, Micromass Limited in September 1997, Wyatt Technology in May 2023 and the BDS Business (as defined below) in February 2026”

Integrated consumables capability and ACQUITY UPLC synergy

Waters is one of the few suppliers that processes silica and polymeric resins, packs columns and distributes its own products; ACQUITY UPLC instruments/columns synergy drives column business

85%
Source evidence
“The Company believes that it is one of the few suppliers that processes silica and polymeric resins, packs columns and distributes its own products.”

Principal competitors

Principal competitors: Agilent, Shimadzu, Bruker, Danaher, Thermo Fisher; consumables also Merck KGaA and GE; BDS markets: Danaher, Revvity, Cytek Biosciences, bioMérieux

90%
Source evidence
“the Company's principal competitors include: Agilent Technologies, Inc., Shimadzu Corporation, Bruker Corporation, Danaher Corporation and Thermo Fisher Scientific Inc.”

China demand volatility

China sales fell 10% in 2024 on regulations and weak macro spending, rebounded 10% in 2025

94%
Source evidence
“2024 sales were impacted by the 10% decline in China sales due to lower demand for our instrument systems and chemistry products as a result of increased government regulations and lower spending by our customers due to macroeconomic conditions”

R&D expenditures and headcount

R&D expenditures: $196M (2025), $183M (2024), $175M (2023); ~1,200 R&D employees at Dec 31, 2025

95%
Source evidence
“The Company's research and development expenditures for 2025, 2024 and 2023 were $196 million, $183 million and $175 million, respectively.”

Risks, financing, and outlook

SpinCo debt and Credit Facility

Assumed $4.0B SpinCo term debt ($3.5B 364-day Tranche A to refinance with bonds; $500M 2-year Tranche B); $1.8B revolver maturing May 2030

97%
Source evidence
“Tranche A is expected to be refinanced with long-term bond financing, while Tranche B is expected to be repaid prior to maturity”

Substantial debt assumed from BDS Business Acquisition

The amount of indebtedness that the Company assumed as a result of the BDS Business Acquisition is substantial and could adversely affect the Company's operational flexibility and increase its borrowing costs

90%
Source evidence
“The amount of indebtedness that the Company assumed as a result of the BDS Business Acquisition is substantial and could adversely affect the Company's operational flexibility and increase its borrowing costs.”

BDS acquisition costs and financing costs

~$82M BDS transaction/integration costs, $20M ERP expenses, ~$16M SpinCo financing costs in 2025 interest; $1.0B buyback authorization through Jan 2028

95%
Source evidence
“approximately $82 million of transaction, integration and other internal costs associated with the BDS Business Acquisition”

FDA and foreign regulatory oversight

A portion of operations subject to FDA and similar foreign regulatory agencies; non-compliance could result in recalls, fines, or restrictions on operations.

95%
Source evidence
“A portion of the Company’s operations are subject to regulation by the FDA and similar foreign regulatory agencies.”

US government policy changes

New US administration downsizing agencies, canceling/delaying contracts and research grants, and altering healthcare advisory panel guidance

90%
Source evidence
“the elimination, downsizing and reduced funding of certain government agencies and programs and the cancellation or delay of government contracts and research grants”

EU data protection regulation with revenue-based fines

EU data protection regulation imposes fines based on a percentage of global revenues; regulators increasingly focus on AI, biometrics and surveillance technologies.

90%
Source evidence
“the European Union, as an example, has enacted a broad data protection regulation with fines based on a percentage of global revenues”

Environmental/regulatory compliance (RoHS, WEEE, FDA QSR, EU IVD Directive)

Subject to EU/China RoHS restrictions, EU WEEE directive, FDA Quality System Regulation and European In-Vitro Diagnostic Directive

85%
Source evidence
“the Company continues to monitor environmental, health and safety regulations ... in particular, European Union and China Restrictions on the use of certain Hazardous Substances in electrical and electronic equipment and European Union Waste Electrical and Electronic Equipment directives”

Hazardous substances and standards-body compliance

Non-compliance with hazardous substance laws could bring civil/criminal penalties and prohibit distribution or sale; ISO certification loss and OSHA fines possible.

85%
Source evidence
“Some of the Company’s operations are subject to domestic and international laws and regulations with respect to the manufacturing, handling, use or sale of toxic or hazardous substances”

Tariff and trade policy risk

Tariffs and retaliation could significantly impact results; Feb 2026 Supreme Court tariff decision adds refund and trade policy uncertainty

95%
Source evidence
“On February 20, 2026, the U.S. Supreme Court rendered a decision invalidating tariffs imposed under the International Emergency Economic Powers Act. This decision introduces uncertainty regarding potential refund processes and future trade policy actions”

China healthcare cost controls (volume-based procurement)

China price regulation including volume-based procurement programs unfavorably impacts revenues and may continue to impact results of operations.

95%
Source evidence
“Governments in China and other countries continue to use various mechanisms to control healthcare expenditures, including increased use of competitive bidding and tenders, price regulation (such as volume-based procurement programs)”

Reimbursement and pricing pressure from payers

Third-party payers increasingly challenge reimbursement models and prices; adverse decisions could significantly reduce reimbursement for procedures using Waters products.

95%
Source evidence
“third-party payers are increasingly challenging the reimbursement models and prices charged for medical products and services”

Macroeconomic, currency, and international operations risks

International operations may be negatively affected by political events, wars, economic conditions, foreign currency fluctuation and regulatory changes; global economic conditions may harm demand

90%
Source evidence
“The Company's international operations may be negatively affected by political events, wars or terrorism, economic conditions, foreign currency fluctuation and regulatory changes”

Product defects, recalls and product liability

Defects could lead to recalls or safety alerts (voluntary or FDA-required), significant costs, lost sales, enforcement actions, and product liability claims possibly exceeding insurance coverage.

90%
Source evidence
“Such events have in the past and could in the future lead to recalls or safety alerts relating to the Company’s products (either voluntary as required by the FDA or similar governmental authorities in other countries)”

AI integration risks in operations and products

Waters continues to integrate AI, including generative AI, into business operations and products; premature or deficient AI use could harm brand, cause regulatory penalties or legal liability, and requires significant investment.

90%
Source evidence
“The Company continues to integrate artificial intelligence (“AI”), including generative AI, into its business operations and products and research further uses and opportunities for AI development.”

Worldwide ERP system dependency and replacement

New worldwide ERP system approved by Board in December 2024, expected to provide enhanced operating efficiencies.

90%
Source evidence
“In December 2024, the Company’s Board of Directors approved the implementation of a new worldwide ERP system”

Customer consolidation and GPO pricing pressure

GPOs and integrated health delivery networks concentrate purchasing decisions, leading to downward pricing pressures.

90%
Source evidence
“Group purchasing organizations and integrated health delivery networks have also served to concentrate purchasing decisions for some customers, which has led to downward pricing pressures.”

Demand risks: research budgets and government funding

Reductions in customers' research budgets or government funding may adversely affect the business; reimbursement changes and government healthcare priorities also affect demand

85%
Source evidence
“Reductions in customers' research budgets or government funding may adversely affect the Company's business.”

Acquisition, JV and divestiture integration risks

Acquisitions may result in dilutive stock issuances, increased debt and contingent liabilities, and additional amortization expense related to intangible assets.

85%
Source evidence
“completing such acquisitions may result in new issuances of the Company’s stock that may be dilutive to current owners; increases in the Company’s debt and contingent liabilities; and additional amortization expense related to intangible assets”

US regulatory uncertainty from current administration

Current US presidential administration and regulatory leadership may create regulatory uncertainty via policy and enforcement changes.

85%
Source evidence
“the current presidential administration and regulatory leadership in the United States may propose, enact or pursue policy, regulatory and enforcement changes that create additional uncertainty for our business”

AI-related risks

Issues and uncertainties related to the development, deployment and use of AI in the Company's business operations and products may result in harm to reputation, regulatory action or legal liability

80%
Source evidence
“Issues and uncertainties related to the development, deployment and use of AI in the Company's business operations and products may result in harm to the Company's reputation, regulatory action or legal liability.”

Rising global protectionism

Increasing global protectionism noted as a risk.

70%
Source evidence
“Increasing global protectionism also”

Material exposure graph

Pharmaceutical customers
Revenue Exposure

Pharmaceutical and life science industries are the most significant end-use markets for HPLC; double-digit 2025 chemistry growth attributed to pharma uptake of columns and testing kits

Relevance 85·Dependency 70·Confidence 95
Source evidence
“The most significant end-use markets for HPLC are those served by the pharmaceutical and life science industries”
China
Regulatory Exposure

China's volume-based procurement, competitive bidding, and price regulation directly pressure Waters' revenues and average selling prices.

Relevance 85·Dependency 60·Confidence 90
Source evidence
“price regulation (such as volume-based procurement programs), government imposed payback provisions, and changes in reimbursement practices and policies on average selling prices for the Company’s products, which unfavorably impact the Company’s revenues”
BD
Legal Exposure

The BDS Business was acquired from BD via Reverse Morris Trust; BD provides transition services and restrictions apply to the Company and SpinCo; integration risk and assumed indebtedness are key risks

Relevance 80·Dependency 70·Confidence 90
Source evidence
“On July 13, 2025, the Company entered into an Agreement and Plan of Merger ... by and among the Company, BD, SpinCo and Beta Merger Sub, Inc.”
Recurring revenues (consumables and service)
Revenue Exposure

Recurring revenues (precision chemistry consumables plus service) grew 8% in 2025 and provide a resilient base against instrument cyclicality

Relevance 80·Dependency 70·Confidence 96
Source evidence
“Recurring revenues (combined sales of precision chemistry consumables and services) increased 8% and 5% in 2025 and 2024, respectively”
FDA and similar foreign regulatory agencies
Regulatory Exposure

FDA and foreign regulators govern product design, manufacturing, labeling, and distribution; failure to comply could result in recalls, fines, or operational restrictions.

Relevance 80·Dependency 65·Confidence 95
Source evidence
“A portion of the Company’s operations are subject to regulation by the FDA and similar foreign regulatory agencies.”
Worldwide ERP system
Technology Dependency

Waters' ERP system is integral to books, records, transactions, and coordinating global manufacturing; disruption or failed ERP replacement could materially harm operations.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“Our worldwide enterprise resource planning (“ERP”) system is integral to our ability to accurately and efficiently maintain our books and records, record transactions, coordinate resource allocation between our manufacturing facilities across the globe”
US and international manufacturing facilities
Manufacturing Dependency

Certain product lines are manufactured in one or a few concentrated plants; prolonged disruption could harm sales and may not be replaceable at other sites or third parties.

Relevance 75·Dependency 65·Confidence 90
Source evidence
“In some instances, the Company may not be able to transition manufacturing to other sites or a third party to replace the lost production.”
China
Demand Driver

China is a disclosed major geography with volatile demand: sales fell 10% in 2024 on regulation and weak macro spending, then grew 10% in 2025

Relevance 75·Dependency 45·Confidence 95
Source evidence
“a 15% decrease in China instrument sales”
Agilent Technologies, Inc.
Competitive Exposure

Agilent is a principal competitor in Waters instrument markets and in consumable columns

Relevance 75·Dependency 40·Confidence 90
Source evidence
“the Company's principal competitors include: Agilent Technologies, Inc., Shimadzu Corporation, Bruker Corporation, Danaher Corporation and Thermo Fisher Scientific Inc.”
Danaher Corporation
Competitive Exposure

Danaher competes in Waters instrument markets and consumable products, and in BDS markets

Relevance 75·Dependency 40·Confidence 90
Source evidence
“In recent years, the Company's principal competitors for consumable products have included: Danaher Corporation, Merck KGaA, Agilent Technologies, Inc., General Electric Company and Thermo Fisher Scientific Inc.”
BDS acquisition financing leverage
Legal Exposure

Assumption of $4.0B SpinCo debt including a 364-day $3.5B tranche requiring refinancing creates near-term financing dependency

Relevance 70·Dependency 60·Confidence 93
Source evidence
“SpinCo borrowed $4.0 billion of unsecured term loans under the SpinCo Credit Agreement”
Singapore
Supplier Dependency

LC instrument systems and components manufacturing is outsourced to contract manufacturing firms in Singapore; the Singapore entity manages all Asian outsourced manufacturing and distribution

Relevance 70·Dependency 55·Confidence 90
Source evidence
“the Company outsources the manufacturing of certain LC instrument systems and components to well-established contract manufacturing firms in Singapore”
Tariffs / trade policy
Geopolitical Exposure

US tariffs, retaliatory tariffs and China export restrictions on manufacturing components could significantly affect operations and cash flows

Relevance 70·Dependency 50·Confidence 94
Source evidence
“These tariffs, any resulting retaliatory tariffs and any related supply-chain disruptions could have a significant impact on the Company’s consolidated statement of operations and statement of cash flows”
Group purchasing organizations
Customer Exposure

GPOs and integrated health delivery networks concentrate customer purchasing decisions, driving downward pricing pressure on Waters products.

Relevance 70·Dependency 50·Confidence 90
Source evidence
“Group purchasing organizations and integrated health delivery networks have also served to concentrate purchasing decisions for some customers, which has led to downward pricing pressures.”
Government research funding
Demand Driver

Reductions in customers' research budgets or government funding may adversely affect demand for Waters products

Relevance 65·Dependency 45·Confidence 85
Source evidence
“Reductions in customers' research budgets or government funding may adversely affect the Company's business.”
Interest rates
Demand Driver

Customer demand in certain businesses depends on capital spending budgets and interest rates, linking monetary conditions to Waters order volumes.

Relevance 65·Dependency 45·Confidence 85
Source evidence
“demand depends on customers’ capital spending budgets, government funding policies and interest rates”
EU data protection regulation
Regulatory Exposure

EU privacy regulation carries fines based on a percentage of global revenues and raises compliance costs; regulators focus on AI, biometrics, and surveillance technologies.

Relevance 65·Dependency 45·Confidence 90
Source evidence
“has enacted a broad data protection regulation with fines based on a percentage of global revenues”
United States
Revenue Exposure

Approximately 39% of the Company's employees are located in the United States

Relevance 60·Dependency 50·Confidence 90
Source evidence
“approximately 39% of the Company's employees located in the United States”
Artificial intelligence / generative AI
Competitive Exposure

Waters is integrating AI including generative AI into operations and products; execution failures could hurt competitiveness if competitors advance faster, and evolving AI regulation adds compliance burden.

Relevance 60·Dependency 40·Confidence 85
Source evidence
“Delays or disruptions in successfully developing and implementing AI as part of the Company’s business activities, products or services could have a negative impact on the Company’s competitiveness”
International operations / FX fluctuation
Currency Exposure

International operations may be negatively affected by foreign currency fluctuation, political events and regulatory changes

Relevance 60·Dependency 40·Confidence 85
Source evidence
“The Company's international operations may be negatively affected by political events, wars or terrorism, economic conditions, foreign currency fluctuation and regulatory changes”
Supply chain / manufacturing components
Cost Driver

China imposed tariffs and export restrictions on certain manufacturing components, affecting the Company's supply chain planning and cost structure

Relevance 55·Dependency 45·Confidence 85
Source evidence
“tariffs and export restrictions on certain manufacturing components imposed by China”
Foreign currency translation
Revenue Exposure

FX translation reduced sales growth by 1% in 2024 and lowered 2024 operating income by approximately $43 million

Relevance 55·Dependency 40·Confidence 90
Source evidence
“the negative effect of foreign currency translation lowered operating income by approximately $43 million during 2024”
US government research funding
Demand Driver

Customers include FDA, EPA, universities and government agencies; agency downsizing and canceled/delayed grants threaten demand

Relevance 55·Dependency 35·Confidence 88
Source evidence
“the cancellation or delay of government contracts and research grants”
Full company information
Latest profile, trading, valuation, and identifier data stored for WAT.
Share price
$449.33
Market cap
$44.12B
Exchange
NYSE
Currency
USD
CEO
Udit Batra
Employees
7,900
IPO date
17/11/1995
Beta
1.149
Last dividend
$0.00
Day range
$446.00 – $466.45
52-week range
$282.77 – $482.28
1-day performance
-2.89%
1-year performance
58.90%
Current drawdown (1Y)
-6.83%
CIK
0001000697
CUSIP
941848103
ISIN
US9418481035
Created
07/12/2025, 15:03:43
Last update
03/11/2026, 04:29:00

Track Waters Corporation with an AI analyst

See which prediction-market events move WAT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to WAT from your Railway `news_articles` table.